Toomas Podar

https://www.etis.ee/CV/Toomas_Podar/est
8.05.1956
7301909
toomas@endokrinoloogia.ee

Teenistuskäik

Töökohad ja ametid
2002–...   
Endokrinoloogiakeskus OÜ, Tegevjuht (1,00)
1998–2000   
Tartu Ülikool, Arstiteaduskond, Külalisprofessor (1,00)
1993–1998   
Tartu Ülikool, Arstiteaduskond, Dotsent (0,50)
1992–1993   
Tartu Ülikool, Arstiteaduskond, Dotsent (1,00)
01.01.1990–31.12.1992   
Pittsburghi Ülikool, Pittsburgh, PA, USA, teadur
1988–1990   
Tartu Ülikool, Arstiteaduskond, Dotsent (1,00)
1980–1988   
Tartu Ülikool, Arstiteaduskond, Assistent (1,00)
 
 
Haridustee
1974–1980   
Tartu Ülikool, arstiteaduskond
1963–1974   
Miina Härma nimeline Tartu 2. keskkool
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2000−2002   
SA TÜK endokrinoloogia osakond, juhataja
1994−1998   
SA Tartu Ülikooli Kliinikum, juhatuse liige
1993−1999   
SA TÜK Endokrinoloogiahaigla, peaarst
1992−1998   
Eesti Endokrinoloogide Selts, esimees
 
 
Teenistuskäigu lisainfo
Eesti Vabariigi Sotsiaalministeeriumi endokrinoloogianõunik, 1993-1998
Eesti Vabariigi Sotsiaalministeeriumi endokrinoloogiakomisjoni liige, 1999-praeguseni;

Kvalifikatsioon

Teaduskraadid
Toomas Podar, doktorikraad, 1994, (juh) -, Incidence of Childhood Onset Type 1 Diabetes Mellitus in Estonia, Tartu Ülikool.
Toomas Podar, magistrikraad (teaduskraad), 1991, (juh) Ronald E. LaPorte, Insulin Dependent Diabetes Mellitus in Native Estonians and Immigrants to Estonia, University of Pittsburgh, Pittsburgh, PA, USA.
Toomas Podar, doktorikraad, 1988, (juh) Valve Saarma, Humoraalse immuniteedi muutused difuusse toksilise struuma ravimisel merkasoliiliga, Moscow I Institute of Medicine.
 
 
Teaduspreemiad ja tunnustused
2008, Toomas Podar, Eesti saadik for the European Foundation for the Study of Diabetes New Horizons Research Initiative
 
 
Teadustöö põhisuunad
VALDKOND: 3. Terviseuuringud; 3.11. Terviseuuringutega seotud uuringud, näiteks biokeemia, geneetika, mikrobioloogia, biotehnoloogia, molekulaarbioloogia, rakubioloogia, biofüüsika ja bioinformaatika
VALDKOND: 3. Terviseuuringud; 3.6. Rahvatervishoid; PÕHISUUND: Suhkurtõve epidemioloogia
VALDKOND: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; PÕHISUUND: Endokrinoloogia
 
 
Lisainfo
Euroopa Komisjoni ekspert EX2002B067058, FP6, FP7, NEST
Hispaania tervishoiuministeeriumi ekspert alates 2006

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2008
Sjølie, A.K.; Klein, R.; Porta, M.; Orchard, T.; Fuller, J.; Parving, H.H.; Bilous, R.; Chaturvedi, N.; DIRECT Programme Study Group (Podar, T.) (2008). Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet, 372 (9647), 1385−1393.
1.1.
2008
Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C.E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B. ... ADVANCE Collaborative Group (Podar, T.) (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358 (24), 2560−2572.
1.1.
2008
Chaturvedi, N.; Porta, M.; Klein, R.; Orchard, T.; Fuller, J.; Parving, HH.; Bilous, R.; Sjølie, AK.; DIRECT Programme Study Group (Podar, T.). (2008). Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet, 372 (9647), 1394−1402.
6.4.
2007
(2007). Tervislik elustiil. . Tartu.
1.1.
2005
Harjutsalo, V.; Podar, T.; Tuomilehto, J. (2005). Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes, 54 (2), 563−569.
1.1.
2005
Pozzilli, P.; Manfrini, S.; Buzzetti, R.; Lampeter, E.; Leeuw, ID.; Iafusco, D.; Prisco, M.; Ionescu-Tirgoviste, C.; Kolouskova, S.; Linn, T.; Ludvigsson, J.; Madacsy, L.; Mrozikiewicz, AS.; Mrozikiewicz, PM.; Podar, T.; Vavrinec, J.; Vialettes, B.; Visalli, N.; Yilmaz, T.; Browne, PD. (2005). Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Res Clin Pract, 68 (3), 258−264.
1.3.
2005
Adojaan, B.; Podar, T.; Märtson, A.; Parv, M. (2005). Luutiheduse näitajad menopausis suhkruhaigetel. Eesti Arst, 8, 527-530.
1.1.
2003
Kalev, I.; Osolin, K.; Pärlist, P.; Zilmer, M.; Rajasalu, T.; Podar, T.; Mikelsaar, AV. (2003). CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. Journal of Diabetes and its Complications, 17 (6), 387−391.
1.1.
2003
Podar, T. (2003). Patient with type 2 diabetes and stroke. Acta Diabetol, S405−S406.
3.1.
2003
Karvonen, M.; Tuomilehto, J.; Podar, T. (2003). Epidemiology of Type I diabetes. Pickup, J.; Williams, G.. Textbook of diabetes. 3rd edition. (5.1−5.14).. Oxford, Boston, Melbourne, Berlin, Paris, Tokyo: Blackwell Science.
1.1.
2002
Podar, T.; Tuomilehto, J. (2002). The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs, 62 (14), 2007−2012.
1.3.
2002
Kalev, I.; Podar, T.; Oselin, K.; Pärlist, P.; Tasa, G.; Mikelsaar, A. (2002). Kemokiiniretseptori CCR5 geeni polümorfism eestlastel ja mutatsiooni ccr5-delta-32 seos diabeediga. Eesti Arst, 2, 62−69.
5.1.
2002
Kalev, I.; Mikelsaar, A.; Podar, T. (2002). A hypothesis about two kind of function of the CC-chemokine receptor CCR5 in the case of diabetes. European Journal of Human Genetics, 10, 163−163.
1.1.
2001
Vides, H.; Nilsson, PM.; Sarapuu, V.; Podar, T.; Isacsson, A.; Schersten, BF. (2001). Diabetes and social conditions in Estonia. A population-based study. European Journal of Public Health, 11, 60−64.
1.1.
2001
Podar, T.; Solntsev, A.; Karvonen, M.; Padaiga, Z.; Brigis, G.; Urbonaite, B.; Viik-Kajander, M.; Reunanen, A.; Tuomilehto, J. (2001). Increasing incidence of childhood-onset type I diabetes in 3 Baltic countries and Finland 1983-1998. Diabetologia, 44, B17−B20.
1.2.
2001
Kalev, I.; Oselin, K.; Pärlist, P.; Podar, T.; Mikelsaar, A. (2001). CC-chemokine receptor CCR5 gene polymorphism analysis in diabetes Type I and Type II patients in Estonia. European Journal of Human Genetics, 9 (269), 269.
1.1.
2000
Podar, T.; Solntsev, A.; Reunanen, A.; Urbonaite, B.; Zalinkevicius, R.; Karvonen, M.; LaPorte, RE.; Tuomilehto, J. (2000). Mortality in patients with childhood onset type 1 diabetes mellitus in Finland, Estonia and Lithuania — Follow-up of nationwide cohorts. Diabetes Care, 23, 290−294.
1.1.
1999
Adojaan, B.; Sabbad, E.; Vähäsalo, P.; Åkerblom, HK.; Podar, T.; Knip, M. (1999). Glutamic acid decarboxylase and islet cell antibodies in healthy Estonian children. Journal of Pediatric Endocrinology and Metabolism, 12, 667−672.
1.1.
1999
Padaiga, Z.; Tuomilehto, J.; Karvonen, M.; Dahlquist, G.; Podar, T.; Adojaan, B.; Urbonaite, B.; Zalinkevicius, R.; Brigis, G.; Virtala, E.; Kohtamaki, K.; Cepaitis, Z.; Tuomilehto-Wolf, E. (1999). Seasonal variation in the incidence of Type 1 diabetes mellitus during 1983 to 1992 in the countries around the Baltic Sea. Diabetic Medicine, 16 (9), 736−743.
1.1.
1999
Podar, T.; Onkamo, P.; Forsen, T.; Karvonen, M.; Tuomilehto-Wolf, E.; Tuomilehto, J. (1999). Neonatal anthropometric measurements and risk of childhood-onset type 1 diabetes. Diabetes Care, 22 (12), 2092−2094.
1.1.
1998
Nejentsev, S.; Koskinen, S.; Sjoroos, M.; Reijonen, H.; Schwartz, EI.; Kovalchuk, L.; Sochnev, A.; Adojaan, B.; Podar, T.; Knip, M.; Simell, O.; Koskenvuo, M.; Akerblom, HK.; Ilonen, J. (1998). Distribution of insulin-dependent diabetes mellitus (IDDM)-related HLA alleles correlates with the difference in IDDM incidence in four populations of the Eastern Baltic region. Tissue Antigens, 52 (5), 473−477.
1.3.
1998
Adojaan, B.; Podar, T. (1998). Lapseeas alanud insuliinsõltuva suhkurtõve immunoloogilised ja geneetilised tegurid Eestis. Eesti Arst, 6, 488-491.
1.1.
1997
Padaiga, Z.; Tuomilehto, J.; Karvonen, M.; Podar, T.; Brigis, G.; Urbonaite, B.; Kohtamäki, K.; Lounamaa, R.; Tuomilehto-Wolf, E.; Reunanen, A. (1997). Incidence trends in childhood onset IDDM in four countries around the Baltic Sea during 1983-1992. Diabetologia, 40, 187−192.
1.1.
1997
Shlik, J.; Aluoja, A.; Vasar, V.; Vasar, E.; Podar, T.; Bradwejn, J. (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry & Neuroscience, 22 (5), 332−340.
1.1.
1996
Veinpalu, M.; Ambos, A.; Velbri, S.; Vaher, Y.; Podar, T. (1996). Urinary iodine excretion in Estonian children. European Journal of Endocrinology, 135 (2), 248−248.
1.1.
1996
Podar, T.; Solntsev, A.; Vali, M.; Vinogradova, T.; Podar, I. (1996). No deterioration of glucose tolerance in weight cycling obese. International Journal of Obesity, 20 (10), 921−924.
1.1.
1996
Podar, T.; Solntsev, A.; Rahu, M.; Leinsalu, M.; Tuomilehto, J.; LaPorte, RE. (1996). Mortality of childhood-onset IDDM patients in Estonia. Diabetologia, 39 (10), 1238−1239.
1.1.
1995
Tuomilehto, J.; Podar, T.; Tuomilehto-Wolf, E.; Virtala, E. (1995). Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents. Diabetologia, 38, 975−982.
3.1.
1994
Tuomilehto, J.; Podar, T.; Adojaan, B.; Kalits, I.; Tuomilehto-Wolf, E.; Lounamaa, R.; Brigis, G.; Urbonaite, B.; Padaiga, Z.; Cepaitis, Z.; Grabauskas, V.; Rewers, M.; Walczak, M.; Shubnikov, E.; Nikitin, J.; LaPorte, RE. (1994). Epidemiology of IDDM in childhood in the Baltic Sea region. Dorman, JS.. Standardization of epidemiologic studies of host susceptibility (13−26).. New York, London: Plenum Publishers Co. (NATO ASI Series).
3.1.
1994
Podar, T.; Tuomilehto, J.; Tuomilehto-Wolf, E.; Dorman, JS.; LaPorte, RE. (1994). The risk of insulin-dependent diabetes in offspring of parents with insulin-dependent diabetes. Dorman,JS.. Standardization of epidemiologic studies of host susceptibility (57−68).. New York, London: Plenum Publishers Co. (Advanced Science Institutes Series).
1.1.
1993
Podar, T.; Shubnikov, E.; Tuomilehto, J.; LaPorte, RE. (1993). Risk of childhood type 1 diabetes for Russians in Estonia and Siberia. International Journal of Epidemiology, 22, 262−267.
1.1.
1993
Podar, T.; LaPorte, RE. (1993). Incidence of childhood diabetes did not increase in Estonia during 1980-89. Diabète & Métabolisme, 19, 361−363.
1.1.
1992
Shubnikov, E.; Podar, T.; Tuomilehto, J.; Nikitin, Y. (1992). Low incidence of insulin-dependent diabetes in the district of Novosibirsk (Soviet Union). Diabetes Care, 15, 915−917.
1.1.
1992
Tuomilehto J, Podar T, Brigis G, Urbonaite B, Rewers M, Adojaan B, Cepaitis Z, Kalits, I.; King, H.; LaPorte, RE.; Lounamaa, R.; Padaiga, Z.; Reunanen, A.; Tuomilehto-Wolf, E.; Walczak, M. (1992). Comparison of the incidence of insulin-dependent diabetes mellitus in childhood among five Baltic populations during 1983–1988. International Journal of Epidemiology, 21, 518−527.
1.1.
1992
Podar, T.; Tuomilehto-Wolf, E.; Tuomilehto, J.; LaPorte, RE.; Adojaan, B. (1992). Insulin-dependent diabetes mellitus in native Estonians and immigrants to Estonia. American Journal of Epidemiology, 135, 1231−1236.
3.1.
1992
Tuomilehto, J.; Podar, T.; Tuomilehto-Wolf, E. (1992). Variation in the insulin-dependent diabetes mellitus (IDDM) in Finland and in the Baltic region - a case of genetic-environmental interaction? Rifkin, H.; Colwell, JA.; Taylor, SI.. Diabetes 1991 (995−1001).. Amsterdam: Elsevier.
3.1.
1992
Tull, E.; Tajima, N.; Podar, T.; Dorman, J.; Moy, C.; LaPorte, R. (1992). Epidemics, migrants and the death of the pancreas. Levy-Marchal, C.; Czernichow, P.. Epidemiology and etiology of insulin-dependent diabetes in the young (56−65).. Basel, München, Paris, London, New York, New Delhi, Bangkok, Singapore, Tokyo, Sydney: Karger. (Pediatric and Adolescent Endocrinology; 21).
3.1.
1992
Reunanen, A.; Podar, T.; Tuomilehto, J.; Kalits, I.; Åkerblom, HK. (1992). Incidence of insulin-dependent diabetes mellitus in children in Finland and Estonia. Levy-Marchal, C.; Czernichow, P.. Epidemiology and etiology of insulin-dependent diabetes in the young (48−51).. Basel, München, Paris, London, New York, New Delhi, Bangkok, Singapore, Tokyo, Sydney: Karger. (Pediatric and Adolescent Endocrinology; 21).
1.1.
1991
Tuomilehto, J.; Podar, T.; Reunanen, A.; Kalits, I.; Lounamaa, R.; Tuomilehto-Wolf, E.; Adojaan, B.; Neff, B.; LaPorte, RE. (1991). Comparison of incidence of IDDM in childhood between Estonia and Finland, 1980–1988. Diabetes Care, 14, 982−988.
1.1.
1990
Kalits, I.; Podar, T. (1990). Incidence and prevalence of type 1 (insulin-dependent) diabetes in Estonia in 1988. Diabetologia, 33 (6), 346−349.
7.04.2019

Toomas Podar

https://www.etis.ee/CV/Toomas_Podar/eng
8.05.1956
7301909
toomas@endokrinoloogia.ee

Career

Institution(s) and position(s)
2002–...   
Endocrinology Centre, Acting manager (1,00)
Tartu University Clinics, Head of the Department of Endocrinology
1998–2000   
University of Tartu, Faculty of Medicine, Visiting Professor (1,00)
1993–1998   
University of Tartu, Faculty of Medicine, Associate Professor (0,50)
1992–1993   
University of Tartu, Faculty of Medicine, Associate Professor (1,00)
01.01.1990–31.12.1992   
University of Pittsburgh, Pittsburgh, PA, USA, postdoctoral fellow
1988–1990   
University of Tartu, Faculty of Medicine, Associate Professor (1,00)
1980–1988   
University of Tartu, Faculty of Medicine, Assistant (1,00)
 
 
Education
1974–1980   
University of Tartu, Faculty of Medicine
1963–1974   
Tartu Second Secondary School
 
 
Additional career information
;

Qualifications

Academic degrees
Toomas Podar, Doctor's Degree, 1994, (sup) -, Incidence of Childhood Onset Type 1 Diabetes Mellitus in Estonia, University of Tartu.
Toomas Podar, Master's Degree, 1991, (sup) Ronald E. LaPorte, Insulin Dependent Diabetes Mellitus in Native Estonians and Immigrants to Estonia (Insulin Dependent Diabetes Mellitus in Native Estonians and Immigrants to Estonia), University of Pittsburgh, Pittsburgh, PA, USA.
Toomas Podar, Doctor's Degree, 1988, (sup) Valve Saarma, Humoraalse immuniteedi muutused difuusse toksilise struuma ravimisel merkasoliiliga (Changes in Humoral Immunity during Methimazole Treatment of Graves' Disease), Moscow I Institute of Medicine.
 
 
Honours & awards
2008, Toomas Podar, Ambassador for Estonia for the European Foundation for the Study of Diabetes New Horizons Research Initiative
 
 
Field of research
FIELD OF RESEARCH: 3. Health; 3.11. Biochemistry, Genetics, Microbiology, Biotechnology, Molecular Biology, Cell Biology, Biophysics and Bioinformatics relating to Health Studies
FIELD OF RESEARCH: 3. Health; 3.6. Public Health Science
FIELD OF RESEARCH: 3. Health; 3.7. Clinical Medicine
 
 
Additional information
Expert of the European Commission, EX2002B067058, FP6, FP7, NEST
Expert of the Spanish Ministry of Health since 2006

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2008
Sjølie, A.K.; Klein, R.; Porta, M.; Orchard, T.; Fuller, J.; Parving, H.H.; Bilous, R.; Chaturvedi, N.; DIRECT Programme Study Group (Podar, T.) (2008). Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet, 372 (9647), 1385−1393.
1.1.
2008
Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C.E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B. ... ADVANCE Collaborative Group (Podar, T.) (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358 (24), 2560−2572.
1.1.
2008
Chaturvedi, N.; Porta, M.; Klein, R.; Orchard, T.; Fuller, J.; Parving, HH.; Bilous, R.; Sjølie, AK.; DIRECT Programme Study Group (Podar, T.). (2008). Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet, 372 (9647), 1394−1402.
6.4.
2007
(2007). Tervislik elustiil. . Tartu.
1.1.
2005
Harjutsalo, V.; Podar, T.; Tuomilehto, J. (2005). Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes, 54 (2), 563−569.
1.1.
2005
Pozzilli, P.; Manfrini, S.; Buzzetti, R.; Lampeter, E.; Leeuw, ID.; Iafusco, D.; Prisco, M.; Ionescu-Tirgoviste, C.; Kolouskova, S.; Linn, T.; Ludvigsson, J.; Madacsy, L.; Mrozikiewicz, AS.; Mrozikiewicz, PM.; Podar, T.; Vavrinec, J.; Vialettes, B.; Visalli, N.; Yilmaz, T.; Browne, PD. (2005). Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Res Clin Pract, 68 (3), 258−264.
1.3.
2005
Adojaan, B.; Podar, T.; Märtson, A.; Parv, M. (2005). Luutiheduse näitajad menopausis suhkruhaigetel. Eesti Arst, 8, 527-530.
1.1.
2003
Kalev, I.; Osolin, K.; Pärlist, P.; Zilmer, M.; Rajasalu, T.; Podar, T.; Mikelsaar, AV. (2003). CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. Journal of Diabetes and its Complications, 17 (6), 387−391.
1.1.
2003
Podar, T. (2003). Patient with type 2 diabetes and stroke. Acta Diabetol, S405−S406.
3.1.
2003
Karvonen, M.; Tuomilehto, J.; Podar, T. (2003). Epidemiology of Type I diabetes. Pickup, J.; Williams, G.. Textbook of diabetes. 3rd edition. (5.1−5.14).. Oxford, Boston, Melbourne, Berlin, Paris, Tokyo: Blackwell Science.
1.1.
2002
Podar, T.; Tuomilehto, J. (2002). The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs, 62 (14), 2007−2012.
1.3.
2002
Kalev, I.; Podar, T.; Oselin, K.; Pärlist, P.; Tasa, G.; Mikelsaar, A. (2002). Kemokiiniretseptori CCR5 geeni polümorfism eestlastel ja mutatsiooni ccr5-delta-32 seos diabeediga. Eesti Arst, 2, 62−69.
5.1.
2002
Kalev, I.; Mikelsaar, A.; Podar, T. (2002). A hypothesis about two kind of function of the CC-chemokine receptor CCR5 in the case of diabetes. European Journal of Human Genetics, 10, 163−163.
1.1.
2001
Vides, H.; Nilsson, PM.; Sarapuu, V.; Podar, T.; Isacsson, A.; Schersten, BF. (2001). Diabetes and social conditions in Estonia. A population-based study. European Journal of Public Health, 11, 60−64.
1.1.
2001
Podar, T.; Solntsev, A.; Karvonen, M.; Padaiga, Z.; Brigis, G.; Urbonaite, B.; Viik-Kajander, M.; Reunanen, A.; Tuomilehto, J. (2001). Increasing incidence of childhood-onset type I diabetes in 3 Baltic countries and Finland 1983-1998. Diabetologia, 44, B17−B20.
1.2.
2001
Kalev, I.; Oselin, K.; Pärlist, P.; Podar, T.; Mikelsaar, A. (2001). CC-chemokine receptor CCR5 gene polymorphism analysis in diabetes Type I and Type II patients in Estonia. European Journal of Human Genetics, 9 (269), 269.
1.1.
2000
Podar, T.; Solntsev, A.; Reunanen, A.; Urbonaite, B.; Zalinkevicius, R.; Karvonen, M.; LaPorte, RE.; Tuomilehto, J. (2000). Mortality in patients with childhood onset type 1 diabetes mellitus in Finland, Estonia and Lithuania — Follow-up of nationwide cohorts. Diabetes Care, 23, 290−294.
1.1.
1999
Adojaan, B.; Sabbad, E.; Vähäsalo, P.; Åkerblom, HK.; Podar, T.; Knip, M. (1999). Glutamic acid decarboxylase and islet cell antibodies in healthy Estonian children. Journal of Pediatric Endocrinology and Metabolism, 12, 667−672.
1.1.
1999
Padaiga, Z.; Tuomilehto, J.; Karvonen, M.; Dahlquist, G.; Podar, T.; Adojaan, B.; Urbonaite, B.; Zalinkevicius, R.; Brigis, G.; Virtala, E.; Kohtamaki, K.; Cepaitis, Z.; Tuomilehto-Wolf, E. (1999). Seasonal variation in the incidence of Type 1 diabetes mellitus during 1983 to 1992 in the countries around the Baltic Sea. Diabetic Medicine, 16 (9), 736−743.
1.1.
1999
Podar, T.; Onkamo, P.; Forsen, T.; Karvonen, M.; Tuomilehto-Wolf, E.; Tuomilehto, J. (1999). Neonatal anthropometric measurements and risk of childhood-onset type 1 diabetes. Diabetes Care, 22 (12), 2092−2094.
1.1.
1998
Nejentsev, S.; Koskinen, S.; Sjoroos, M.; Reijonen, H.; Schwartz, EI.; Kovalchuk, L.; Sochnev, A.; Adojaan, B.; Podar, T.; Knip, M.; Simell, O.; Koskenvuo, M.; Akerblom, HK.; Ilonen, J. (1998). Distribution of insulin-dependent diabetes mellitus (IDDM)-related HLA alleles correlates with the difference in IDDM incidence in four populations of the Eastern Baltic region. Tissue Antigens, 52 (5), 473−477.
1.3.
1998
Adojaan, B.; Podar, T. (1998). Lapseeas alanud insuliinsõltuva suhkurtõve immunoloogilised ja geneetilised tegurid Eestis. Eesti Arst, 6, 488-491.
1.1.
1997
Padaiga, Z.; Tuomilehto, J.; Karvonen, M.; Podar, T.; Brigis, G.; Urbonaite, B.; Kohtamäki, K.; Lounamaa, R.; Tuomilehto-Wolf, E.; Reunanen, A. (1997). Incidence trends in childhood onset IDDM in four countries around the Baltic Sea during 1983-1992. Diabetologia, 40, 187−192.
1.1.
1997
Shlik, J.; Aluoja, A.; Vasar, V.; Vasar, E.; Podar, T.; Bradwejn, J. (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry & Neuroscience, 22 (5), 332−340.
1.1.
1996
Veinpalu, M.; Ambos, A.; Velbri, S.; Vaher, Y.; Podar, T. (1996). Urinary iodine excretion in Estonian children. European Journal of Endocrinology, 135 (2), 248−248.
1.1.
1996
Podar, T.; Solntsev, A.; Vali, M.; Vinogradova, T.; Podar, I. (1996). No deterioration of glucose tolerance in weight cycling obese. International Journal of Obesity, 20 (10), 921−924.
1.1.
1996
Podar, T.; Solntsev, A.; Rahu, M.; Leinsalu, M.; Tuomilehto, J.; LaPorte, RE. (1996). Mortality of childhood-onset IDDM patients in Estonia. Diabetologia, 39 (10), 1238−1239.
1.1.
1995
Tuomilehto, J.; Podar, T.; Tuomilehto-Wolf, E.; Virtala, E. (1995). Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents. Diabetologia, 38, 975−982.
3.1.
1994
Tuomilehto, J.; Podar, T.; Adojaan, B.; Kalits, I.; Tuomilehto-Wolf, E.; Lounamaa, R.; Brigis, G.; Urbonaite, B.; Padaiga, Z.; Cepaitis, Z.; Grabauskas, V.; Rewers, M.; Walczak, M.; Shubnikov, E.; Nikitin, J.; LaPorte, RE. (1994). Epidemiology of IDDM in childhood in the Baltic Sea region. Dorman, JS.. Standardization of epidemiologic studies of host susceptibility (13−26).. New York, London: Plenum Publishers Co. (NATO ASI Series).
3.1.
1994
Podar, T.; Tuomilehto, J.; Tuomilehto-Wolf, E.; Dorman, JS.; LaPorte, RE. (1994). The risk of insulin-dependent diabetes in offspring of parents with insulin-dependent diabetes. Dorman,JS.. Standardization of epidemiologic studies of host susceptibility (57−68).. New York, London: Plenum Publishers Co. (Advanced Science Institutes Series).
1.1.
1993
Podar, T.; Shubnikov, E.; Tuomilehto, J.; LaPorte, RE. (1993). Risk of childhood type 1 diabetes for Russians in Estonia and Siberia. International Journal of Epidemiology, 22, 262−267.
1.1.
1993
Podar, T.; LaPorte, RE. (1993). Incidence of childhood diabetes did not increase in Estonia during 1980-89. Diabète & Métabolisme, 19, 361−363.
1.1.
1992
Shubnikov, E.; Podar, T.; Tuomilehto, J.; Nikitin, Y. (1992). Low incidence of insulin-dependent diabetes in the district of Novosibirsk (Soviet Union). Diabetes Care, 15, 915−917.
1.1.
1992
Tuomilehto J, Podar T, Brigis G, Urbonaite B, Rewers M, Adojaan B, Cepaitis Z, Kalits, I.; King, H.; LaPorte, RE.; Lounamaa, R.; Padaiga, Z.; Reunanen, A.; Tuomilehto-Wolf, E.; Walczak, M. (1992). Comparison of the incidence of insulin-dependent diabetes mellitus in childhood among five Baltic populations during 1983–1988. International Journal of Epidemiology, 21, 518−527.
1.1.
1992
Podar, T.; Tuomilehto-Wolf, E.; Tuomilehto, J.; LaPorte, RE.; Adojaan, B. (1992). Insulin-dependent diabetes mellitus in native Estonians and immigrants to Estonia. American Journal of Epidemiology, 135, 1231−1236.
3.1.
1992
Tuomilehto, J.; Podar, T.; Tuomilehto-Wolf, E. (1992). Variation in the insulin-dependent diabetes mellitus (IDDM) in Finland and in the Baltic region - a case of genetic-environmental interaction? Rifkin, H.; Colwell, JA.; Taylor, SI.. Diabetes 1991 (995−1001).. Amsterdam: Elsevier.
3.1.
1992
Tull, E.; Tajima, N.; Podar, T.; Dorman, J.; Moy, C.; LaPorte, R. (1992). Epidemics, migrants and the death of the pancreas. Levy-Marchal, C.; Czernichow, P.. Epidemiology and etiology of insulin-dependent diabetes in the young (56−65).. Basel, München, Paris, London, New York, New Delhi, Bangkok, Singapore, Tokyo, Sydney: Karger. (Pediatric and Adolescent Endocrinology; 21).
3.1.
1992
Reunanen, A.; Podar, T.; Tuomilehto, J.; Kalits, I.; Åkerblom, HK. (1992). Incidence of insulin-dependent diabetes mellitus in children in Finland and Estonia. Levy-Marchal, C.; Czernichow, P.. Epidemiology and etiology of insulin-dependent diabetes in the young (48−51).. Basel, München, Paris, London, New York, New Delhi, Bangkok, Singapore, Tokyo, Sydney: Karger. (Pediatric and Adolescent Endocrinology; 21).
1.1.
1991
Tuomilehto, J.; Podar, T.; Reunanen, A.; Kalits, I.; Lounamaa, R.; Tuomilehto-Wolf, E.; Adojaan, B.; Neff, B.; LaPorte, RE. (1991). Comparison of incidence of IDDM in childhood between Estonia and Finland, 1980–1988. Diabetes Care, 14, 982−988.
1.1.
1990
Kalits, I.; Podar, T. (1990). Incidence and prevalence of type 1 (insulin-dependent) diabetes in Estonia in 1988. Diabetologia, 33 (6), 346−349.
7.04.2019
Detailne otsing
  • Leitud 1 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
TK2005 (2004310)Diabeet Euroopas – ennetus muutes elustiili, füüsilist aktiivsust ja toitumist01.03.200531.08.2008Toomas PodarEndokrinoloogiakeskus OÜ3 332,74 EUR